Neurofibromatosis type 2 (NF2) is a monogenic dominantly inherited dis
ease that predisposes to the development of tumors of the nervous syst
em, particularly meningiomas and schwannomas. The gene which, when alt
ered, causes NF2, is localized on chromosome 22 and has recently been
identified. The NF2 gene is also the site of somatic mutation in tumor
s, suggesting that it might have a tumor suppressor activity. We here
report a screening method for the detection of point mutations in NF2
which takes advantage of denaturing gradient gel electrophoresis (DGGE
). This method efficiently screens 95% of the coding sequence and 90%
of intron/exon junctions. When applied to 91 unrelated NF2 patients, i
t enabled the identification of 32 germ-line mutations. Since mutation
s are found in only one third of the patients, it is expected that mut
ations or deletions affecting the promoter and/or intronic regions of
the NF2 gene occur frequently. The characterized mutations are prefere
ntially located within the 5' half of the gene. Most of them are predi
cted to lead to the synthesis of a truncated protein. A search for gen
otype/phenotype correlations showed that, at least in this series of p
atients, mild manifestations of the disease were associated with mutat
ions which preserve the C-terminal end of the protein. (C) 1995 Wiley-
Liss, Inc.